143 related articles for article (PubMed ID: 33205588)
1. Chemical Translational Biology: Redefining Druggability of Protein-Protein Interactions.
Cesa LC
Chembiochem; 2021 Mar; 22(6):985-987. PubMed ID: 33205588
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family.
Lee EF; Czabotar PE; Smith BJ; Deshayes K; Zobel K; Colman PM; Fairlie WD
Cell Death Differ; 2007 Sep; 14(9):1711-3. PubMed ID: 17572662
[No Abstract] [Full Text] [Related]
3. Bcl-2 antagonists and cancer: from the clinic, back to the bench.
Esposti MD
Cell Death Dis; 2010 Apr; 1(4):e37. PubMed ID: 21364644
[No Abstract] [Full Text] [Related]
4. Preparing Samples for Crystallization of Bcl-2 Family Complexes.
Kvansakul M; Czabotar PE
Methods Mol Biol; 2016; 1419():213-29. PubMed ID: 27108442
[TBL] [Abstract][Full Text] [Related]
5. Molecular dynamics study of small molecule inhibitors of the Bcl-2 family.
Acoca S; Cui Q; Shore GC; Purisima EO
Proteins; 2011 Sep; 79(9):2624-36. PubMed ID: 21721047
[TBL] [Abstract][Full Text] [Related]
6. Teaching an old drug new tricks: Actinomycin D synergistically enhances sensitivity to the Bcl-2 antagonist ABT-737.
Krystal GW
Cancer Biol Ther; 2010 Nov; 10(9):930-2. PubMed ID: 20935462
[No Abstract] [Full Text] [Related]
7. Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-X
Roy MJ; Vom A; Okamoto T; Smith BJ; Birkinshaw RW; Yang H; Abdo H; White CA; Segal D; Huang DCS; Baell JB; Colman PM; Czabotar PE; Lessene G
J Med Chem; 2021 May; 64(9):5447-5469. PubMed ID: 33904752
[TBL] [Abstract][Full Text] [Related]
8. Conformational changes in Bcl-2 pro-survival proteins determine their capacity to bind ligands.
Lee EF; Czabotar PE; Yang H; Sleebs BE; Lessene G; Colman PM; Smith BJ; Fairlie WD
J Biol Chem; 2009 Oct; 284(44):30508-17. PubMed ID: 19726685
[TBL] [Abstract][Full Text] [Related]
9. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
Bruncko M; Oost TK; Belli BA; Ding H; Joseph MK; Kunzer A; Martineau D; McClellan WJ; Mitten M; Ng SC; Nimmer PM; Oltersdorf T; Park CM; Petros AM; Shoemaker AR; Song X; Wang X; Wendt MD; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
J Med Chem; 2007 Feb; 50(4):641-62. PubMed ID: 17256834
[TBL] [Abstract][Full Text] [Related]
10. Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein interaction: proof-of-concept of an in vivo chemopotentiator ABT-737.
Stauffer SR
Curr Top Med Chem; 2007; 7(10):961-5. PubMed ID: 17508927
[TBL] [Abstract][Full Text] [Related]
11. Multiple ligand simultaneous docking: orchestrated dancing of ligands in binding sites of protein.
Li H; Li C
J Comput Chem; 2010 Jul; 31(10):2014-22. PubMed ID: 20166125
[TBL] [Abstract][Full Text] [Related]
12. Identification of Small Inhibitory Molecules Targeting the Bfl-1 Anti-Apoptotic Protein That Alleviates Resistance to ABT-737.
Mathieu AL; Sperandio O; Pottiez V; Balzarin S; Herlédan A; Elkaïm JO; Fogeron ML; Piveteau C; Dassonneville S; Deprez B; Villoutreix BO; Bonnefoy N; Leroux F
J Biomol Screen; 2014 Aug; 19(7):1035-46. PubMed ID: 24809353
[TBL] [Abstract][Full Text] [Related]
13. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.
van Delft MF; Wei AH; Mason KD; Vandenberg CJ; Chen L; Czabotar PE; Willis SN; Scott CL; Day CL; Cory S; Adams JM; Roberts AW; Huang DC
Cancer Cell; 2006 Nov; 10(5):389-99. PubMed ID: 17097561
[TBL] [Abstract][Full Text] [Related]
14. [Progress in small-molecule inhibitors of Bcl-2 family proteins].
Tang Y; Zhang DY; Wu XM
Yao Xue Xue Bao; 2008 Jul; 43(7):669-77. PubMed ID: 18819468
[TBL] [Abstract][Full Text] [Related]
15. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
Kuroda J; Kimura S; Strasser A; Andreeff M; O'Reilly LA; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Tabe Y; Taniwaki M; Maekawa T
Cell Death Differ; 2007 Sep; 14(9):1667-77. PubMed ID: 17510658
[TBL] [Abstract][Full Text] [Related]
16. Development of 3-phenyl-N-(2-(3-phenylureido)ethyl)-thiophene-2-sulfonamide compounds as inhibitors of antiapoptotic Bcl-2 family proteins.
Yang C; Chen S; Zhou M; Li Y; Li Y; Zhang Z; Liu Z; Ba Q; Li J; Wang H; Yan X; Ma D; Wang R
ChemMedChem; 2014 Jul; 9(7):1436-52. PubMed ID: 24782462
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?
Labi V; Grespi F; Baumgartner F; Villunger A
Cell Death Differ; 2008 Jun; 15(6):977-87. PubMed ID: 18369371
[TBL] [Abstract][Full Text] [Related]
18. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.
High LM; Szymanska B; Wilczynska-Kalak U; Barber N; O'Brien R; Khaw SL; Vikstrom IB; Roberts AW; Lock RB
Mol Pharmacol; 2010 Mar; 77(3):483-94. PubMed ID: 20038611
[TBL] [Abstract][Full Text] [Related]
19. Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation.
Doi K; Li R; Sung SS; Wu H; Liu Y; Manieri W; Krishnegowda G; Awwad A; Dewey A; Liu X; Amin S; Cheng C; Qin Y; Schonbrunn E; Daughdrill G; Loughran TP; Sebti S; Wang HG
J Biol Chem; 2012 Mar; 287(13):10224-10235. PubMed ID: 22311987
[TBL] [Abstract][Full Text] [Related]
20. Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.
Chen S; Dai Y; Pei XY; Grant S
Mol Cell Biol; 2009 Dec; 29(23):6149-69. PubMed ID: 19805519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]